< Back to previous page

Project

PEA histone modification proteomics

Olink's groundbreaking proteomics panels help scientists discover human protein biomarkers. Proximity Extension Assay (PEA) technology measures up to 1463 unique proteins in 88 samples simultaneously, starting from less than 3 microliters from nearly any type of biological sample. Unique application domains are located where mass spectrometry (MS) based proteomics is suboptimal. Samples such as cerebrospinal fluid (CSF), microdialysis samples, or extracellular vesicles, usually have too limited input material to be used for MS-based proteomics. Blood samples are also problematic for MS proteomics because the large excess of globin proteins makes it difficult to measure other proteins. The aim of this project is to offer PEA technology in a semi-automatic workflow to academic and industrial partners within UGent’s NXTGNT facility. An applied research part aims to develop, validate and ultimately valorize a PEA histone modification panel.

Date:1 Mar 2021 →  31 Dec 2023
Keywords:Proximity Extension Assay (PEA) technology, proteomics, Olink
Disciplines:Other pharmaceutical sciences not elsewhere classified, Biomarker evaluation, Biomarker discovery